Member Info for Merchantbanker

I thought the webinar and latest PR push showed excellent progress and superb value on offer.

Finding a project partner will be a huge catalyst and plus what they have already delivered should bring the share price to a level to enable them to get the warrants away and put cash in the bank. TBH it should be up there now, but clearly for some reason we are not seeing the valuation match the progress of the company. It does seem to come down to funding and people concerned about how a company with a £6m valuation are going to fund a $62m investment. Well that's what the PFS is for. It clearly shows a very attractive project, and they are raising funds against a project with $1bn free cash flows and not against a £6m balance sheet. The pilot and then full production approach will enable them to retain more equity in the project.

In terms of the speed of the project, there is a very clear plan to match production with demand and they are a long way ahead of other potential projects when the time is right to supply the market. There is no point producing more than the market will take and giving up more equity to be able to do that. It's a very well thought out approach to see this through with the largest retained interest, rather than give too much away early doors.

If demand takes off sooner than the current model projects, there will be a queue of companies wanting to get involved to access what Orom Cross has to offer, and with such a shortfall in short term projects to tackle supply issues, the value of Orom cross increases so Blencowe will achieve a better valuation. They are already looking at routes to market, and there is a high likelihood at the right time in the demand cycle somebody will want to secure up their supply chain.

In this current market a company that is underpinned by an cash generative project like this should be a stand out investment opportunity. It's almost certain at some point it will peak someones interest when PI's least expect it and this moves quickly when any material amount is bought on the open market. With these stocks it's all about popularity, and at the moment BRES isn't popular, but it is at the stage where one event can change this significantly.

And around 20% of the placing at 14p is taken up by the new management

It's in the "Key terms of the acquisition" - the bit at the bottom of the RNS that no doubt most people have not read!

£5.5m consideration, 50m shares. Can work it out at 11p per share.

I think they just happen to be in London this week, its not timed around news. I think people look at the share price and complain the company are not doing enough so an investor meeting might help. I think they have communicated well exactly where we are at and i don't believe lack of investor knowledge or resource is the problem. People are just waiting to see investment at the right valuation to carry this forward and that ultimately when the time is right to proceed with the project that the investment will be on favourable terms for shareholders, which no doubt it will be. The RAB investment timing and valuation was a short term set back in valuation, but a medium term catalyst. We now have an investor with a track record of winners in mining looking for a substantial return from 5p. It's a good gig to be on the same train as they are, and even better 20% cheaper. At this price there's 100% gain to get to the RAB warrant price.

Pre feasibility study is a few weeks away now. There is every indication that this will prove a substantially attractive project for investors both as a graphite source and a sustainable source project. Being around 12 months away from progressing to a pilot plant, decisions and investments will need to be made before then. We are still priced as an exploration company and undervalued on the asset size, but this will quickly move to being a producer and that value appreciation will climb quickly with it. To be at a stage where no further drilling is required for a 20 year mining life on a fraction of the resource, with low operating cost mining in a supportive jurisdiction is a great place to be. Graphite sourcing will only become more critical and there is every chance that in the coming months Graphite will have it's day in the sun as Mike is expecting. With a Nickel drilling program to be carried out concurrently, lots to look forward to.

People moaning the company gave it away too cheap to RAB at 5p, then selling at 4p!

Value will come - 5p RAB investment shouldn't limit the share price as they have got in on the cheap, pulled the company's pants down really. At least they will be held onto and there wont be huge supply of overhang. Other institutions will have to buy on the open market.

Good for RAB being satisfied to invest derisked on the JORC. They shouldn't get the opportunity to buy at the pre JORC price as clearly a 50% upgrade should command a premium, but that's the way the market goes. You could argue it was widely anticipated what the results would be, but hard to argue MCAP is a fair valuation down here.

As Mike says the next milestones are the ones where they can start to show the value to the market in moving forward towards production. Still expect interest to grow and hopefully by the time the PFS is ready, we are already starting to close the value gap.

I would be much higher buying at todays price than selling.

Mindset of the Board evident front the heading page of the Presentation:

"Building a portfolio of sustainable green battery metals projects."

I think they see the added value they can deliver for the £800k far exceeding the dilution.

Short term the 5p tagline may set us back, but at least we have no question of a placing hanging over us where they would be at the mercy of a discount placing. This is positive, clearly stock that will be held long term. I think they could have achieved a much better valuation, but it will allow new investors to build at this level and form a new base. You could easily still find a case this should be valued significantly higher, and thats a good place for new investors coming in.

PFS wont be far away now. Offtake partners comes next. That's when achieving higher value is key.

I paid a premium for £2k worth earlier. Wouldn't normally do that but seems this is the week for top ups, rather get them early as premium can soon be made up.
IG current quote 3.9976 for £2k

3.9978 to buy £5k worth

Twatcher - what are you on about. I dont post here anymore because its full of idiots. Got better things to do with my time. Just had a bit of time to kill this morning and made the mistake of reading half a dozen comments on here.

Whatever you think the point is Omega are right at the final hurdle of getting their test approved and once they pass that barrier to entry opportunities will far exceed capacity.

So much crap criticising omega and most of it is totally beyond their control.

Here is a list of companies that have been promising Antigen tests for as long as Omega have:

Mologic
Vatic
Avacta
Novacyt
Aptamer

Just a short list of ones i can think of that are of interest to investors. But they are all in a similar position. I would argue Omegas test is a closer than all of these, omega are ahead with the UK Government link and the DAM contract puts them ahead. Only Surescreen are ahead of Omega and we cant think why because Omega have a similar product.

The problems are changing regulations and government and regulator incompetencies.

The UK industry lacked capacity and product. Omega have delivered on this.

There is still a huge opportunity out there. UK manufactured tests are still going to happen. Testing will still be around long enough for Omega to make significant profits.

Self test approval will be a huge catalyst. The DAM agreement is superb and promised to be first of many.

So yes is super disappointing the position we are in but 40p is crazy cheap. This will come good and the profits will be in excess of the MCAP which still opens up the £2+ Share price targets many have had

This list is for professional use tests only.

Once Omega gain self test approval, that puts their product right at the top of the food chain. Regulation is going to make lots of tests that were allowed to fast track approvals disappear.

Th crappy innova test was a billion $ product. The success of the Visitect test will only be limited by how many can be produced.

Yeah I know people are fed up with waiting, but what we are waiting for is extremely valuable and will trump what other companies have achieved and put them in a fantastic position to start making the huge sums of money we all expect.

I’ve also sold my 1.3m holding as I’m worried about who’s gonna win the 13.15 at Goodwood today

By the end of the year abdx will have capacity to produce 156m tests per year. Non or delayed payment for around 500k tests will be small change.
This I’m sure will be settled, tests have been used. In the meantime they just need to show that the heightened operational activity is delivering commercial traction.

This company know exactly what they are doing. It will take off very quickly. Self test approval will be open the flood gates. They know it and are prepared for it.

People losing their sht because self test approval didnt happen in July - well they are that confident they have been manufacturing them as self tests since June. Business doesn't stop at the end of a calendar month. This will be well worth waiting for, as promised by CK one of the first UK made self tests and available for DHSC procurement once achieved self test.
https://twitter.com/MerchantBanke18/status/1421129085233807360?s=20

Yawn

Q78 - well yeah thats exactly what they have been saying - waiting for DHSC test - casetting and pouching in the meantime.

Q73 - FDA approvals - were GDR part of the Radx fast track program and awarded $10m like our partner? Do GDR have high quality lateral flow test matching the requirement of FDA? Have GDR just been acquired by Gates?

In answer to Q205 - As Colin King has said, the Visitect test once it gets self test approval would be available for future DHSC purchase

Q29 - The advantage of ODX strategy in having a diverse portfolio is they can flex capacity to demand. I dont think anyone has had high hopes for significant sales volumes in triple antibody test.

You are full of crap looking for holes to pick to suit your agenda.

Thanks for joining 3 days ago and wasting your 7th all time post on that.......

Statistics also state that doing the opposite to what told by a BB that is clearly full of scum under multiple alias trying to talk people out of their positions pays off

Collin clearly had hopes of the gov contract then.... it said exploring options to achieve these targets. The equity raised would have made things very tight to fund it themselves. Simple fact is having the gov contract which enables them to produce any test is an excellent bit of business, with loaned equipment meaning less cash required to expand. In reality, because of the delay in self test approvals they haven't missed out on sales. Self test market is where the money will be made. This is why you don't see the visitect available for sale anywhere for professional use.